文献速递骨质疏松与代谢性骨病

地舒单抗治疗患者中的神经精神不良反应:两例病例报告及FDA不良事件报告系统(FAERS)数据回顾

Neuropsychiatric adverse reactions in patients treated with denosumab: two case reports and a review of data from the FDA Adverse Event Reporting System (FAERS).
PubMed 文献 · Osteoporos Int · 2023-07-05

本文报告两例既往存在神经生物学易感性的老年女性,在连续接受地舒单抗后反复出现急性意识模糊或抑郁复发伴焦虑与精神运动抑制,Naranjo量表评分分别为6分和7分,提示很可能存在因果关系;并对2012至2022年FAERS数据库中地舒单抗相关病例作描述性回顾,作者建议对这类患者用药后保持谨慎并密切监测。

要点

  • 两例均为81岁女性,分别在连续使用地舒单抗后反复出现神经精神症状,Naranjo评分6分和7分提示很可能相关。
  • FAERS中91,151例地舒单抗暴露病例里,5.7%涉及精神/神经障碍,其中23.8%为认知损害、抑郁/情绪障碍或精神运动迟滞。
  • 作者建议对存在神经生物学易感性的患者使用地舒单抗后保持谨慎并密切监测。

核心结论

  • 地舒单抗可能通过RANKL阻断及随后的免疫炎症改变引起短暂但严重的神经精神症状,至少见于既往存在神经生物学易感性的受试者。
  • 作者建议对这类患者在地舒单抗给药后保持谨慎并密切监测。

研究设计与样本

  • 两例病例报告,加上对2012年至2022年FAERS数据库中所报告相似病例的描述性回顾。
  • FAERS分析仅保留由医疗专业人员报告、且将地舒单抗编码为唯一可疑药物的病例。

主要发现

  • 一名81岁、既往有轻度认知损害的妇女出现两次急性意识模糊发作;另一名81岁、抑郁处于缓解期的妇女出现两次抑郁复发,伴焦虑和精神运动抑制;两例均发生在连续给予地舒单抗之后,且无潜在钙/磷失衡。
  • 两例的Naranjo不良反应概率量表评分分别为6分和7分,提示很可能存在因果关系。
  • FAERS中报告的地舒单抗暴露病例共91,151例,其中5.7%与精神/神经障碍相关,而这些病例中23.8%对应认知损害、抑郁/情绪障碍或精神运动迟滞。

关键数值与推荐

  • Naranjo不良反应概率量表评分:第一例6分,第二例7分,均提示很可能存在因果关系。
  • FAERS中地舒单抗暴露病例91,151例,5.7%涉及精神/神经障碍,其中23.8%为认知损害、抑郁/情绪障碍或精神运动迟滞。

临床怎么用

  • 作者建议对既往存在神经生物学易感性的患者,在地舒单抗给药后保持谨慎并密切监测。

局限性

  • 原文为病例报告加FAERS描述性回顾,仅保留医疗专业人员报告且地舒单抗为唯一可疑药物的病例。
  • 作者在结论中使用「may cause」表述,提示因果关系需进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Denosumab is a human monoclonal antibody indicated for patients with osteoporosis and a high risk of fractures. It targets RANKL, the receptor activator of NF-κB (RANK) ligand, blocking RANKL-RANK interaction and leading to rapid osteoclast-mediated bone resorption inhibition. But RANK is widely expressed in neurons, microglia, and astrocytes. RANKL/RANK/NF-κB system can play an important role in the neuroinflammatory response, depressive behavior, memory impairments, and neurotrophism. We present two well-documented case reports of recurrent neuropsychiatric manifestations in patients treated with denosumab and a descriptive review of similar cases reported to the Food and Drug Administration Adverse Event Reporting System (FAERS) database between 2012 and 2022. Only those reported by healthcare professionals, coding denosumab as the only suspected drug, were retained. An 81-year-old woman with pre-existing mild cognitive impairment suffered two acute confusional episodes and another 81-year-old woman with depression in remission suffered two depressive recurrences with anxiety and psychomotor inhibition, in both cases following sequential administrations of denosumab without underlying calcium/phosphate imbalance. Scores on Naranjo Adverse Drug Reaction Probability Scale were 6 and 7, respectively, suggesting a probable causal relationship. Of the 91,151 cases with denosumab exposure reported to FAERS, 5.7% were related to psychiatric/neurological disorders and 23.8% of these corresponded to cognitive impairment, depressive/mood disturbances, or psychomotor retardation. Denosumab may cause transient but severe neuropsychiatric symptoms by several mechanisms involving RANKL blockade and subsequent immuno-inflammatory changes, at least in subjects with pre-existing neurobiological vulnerability. We recommend caution and careful monitoring of these patients following denosumab administrations.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Oteo-Álvaro Á, García CG, Sánchez AI, et al. Neuropsychiatric adverse reactions in patients treated with denosumab: two case reports and a review of data from the FDA Adverse Event Reporting System (FAERS). Osteoporos Int. 2023. PMID: 37405407. doi:10.1007/s00198-023-06838-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。